Abstract: Disclosed is a pharmaceutical composition and health food comprising herb extracts of one or more herbs selected from the group consisting of Puerariae Radix, Bombycis corpus and Araliae Continentalis Radix. The herb medicine of this invention comprising a single or mixed composition may be useful for the prevention and treatment of renal diseases as well as improvement of renal functions.

Abstract: Disclosed is a pharmaceutical composition and health food comprising herb extracts of one or more herbs selected from the group consisting of Puerariae Radix, Bombycis corpus and Araliae Continentalis Radix. The herb medicine of this invention comprising a single or mixed composition may be useful for the prevention and treatment of renal diseases as well as improvement of renal functions.

Abstract: Disclosed herein is a composition for the treatment bone fracture comprising N-hydroxy-4-{5-[4-( 5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxyl-benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl) phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salts thereof as a medicinally effective ingredient. The composition of the present invention can significantly reduce the volume of bony callus, and increase bony density and strength of bony callus, and decrease the contents of connective tissue and cartilage tissue in bony callus, and thus promote loss and ossification of the bony callus formed during the fracture healing process. Therefore, the composition of the present invention is useful for the treatment of bone fracture.

Abstract: This invention relates to a pharmaceutical composition and health food comprising herb extracts of one or more herbs selected from the group consisting of Puerariae Radix, Bombycis corpus and Araliae Continentalis Radix. The herb medicine of this invention comprising a single or mixed composition may be useful for the prevention and treatment of renal diseases as well as improvement of renal functions.

Abstract: Disclosed herein is a composition for the treatment bone fracture comprising N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxyl-benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or pharmaceutically acceptable salts thereof as a medicinally effective ingredient. The composition of the present invention can significantly reduce the volume of bony callus, and increase bony density and strength of bony callus, and decrease the contents of connective tissue and cartilage tissue in bony callus, and thus promote loss and ossification of the bony callus formed during the fracture healing process. Therefore, the composition of the present invention is useful for the treatment of bone fracture.

Abstract: The present invention relates to a radionuclide-chitosan complex solution and its preparation method, and more particularly to the radionuclide-chitosan complex solution having a viscosity of 300˜2,400 cps, comprising an aqueous chitosan solution or a freeze-dried chitosan labeled with a radionuclide. The radionuclide-chitosan complex solution according to the present invention has a stable gelation state at a target region when injected into the body while maintaining a labeling yield of radioisotope to chitosan above 99%. Side effects may be minimized and treatment efficiency may be increased when injected to a patient.

Abstract: Disclosed is a composition for treating prostate cancer. The composition for treating prostate cancer comprises as an effective ingredient a radioisotope-chitosan complex that includes a therapeutic radioisotope emitting beta radiation and chitosan. Also, the present invention discloses a kit for preparing the composition. When directly administered to a prostate cancer tissue, the radioisotope- chitosan complex is deposited in the applied target site while not leaking from the applied target site, and strongly inhibits the growth of prostate cancer cells while minimizing the side effects of conventional therapies, including urinary incontinence, urethral stricture and rectal bleeding. In addition, the radioisotope-chitosan complex may be used as an effective therapeutic agent for hormone-independent prostate cancer that is resistant to hormone therapy.